Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > results are good

<< Previous

Bullboard Posts

Next >>

Comment by Rumpl3StiltSkinon Nov 30, 2021 1:14am

202 Views

Post# 34178717

RE:RE:RE:results are good

WOW, Still trying to wrap my head around this latest great news!!!

CancerSlayer wrote:

riverrrow wrote: What I like is that there are 4 patients CR at 450 days. Those patients must be very happy indeed. GLTA.

I like that too!...especially when you consider 2 of the 4 (from ph 1b) only received a single treatment & the other 2 of 4 received "unoptimized" treatments, highlighting this tech's potential/durability compared to currently approved treatments.

Also, for the "evaluable" optimized ph 2 patients, we are currently sitting at a 73% CR rate (of the 11 evaluable patients, there are 8 CRs, 2 PRs & 1 NR...with the 1 NR potentially having been a CR as enrique stated). And the CR continues to trend higher as evidenced in the 5 most recently treated patients (at 80%). This latest news couldn't be better imo.